No Data
No Data
William Blair Remains a Buy on Vigil Neuroscience Inc (VIGL)
Vigil Neuroscience Presented Data Highlighting Its Oral Small Molecule Program, Including Its Lead Clinical Candidate VG-3927, In Two Oral Presentations At The AD/PD 2025 International Conference On Alzheimer's And Parkinson's Diseases
Vigil Neuroscience Presents Data on Its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD 2025 International Conference
Vigil Neuroscience Reports 2024 Results and Clinical Progress
Express News | Vigil Neuroscience- Files Prospectus to Offer & Resale, From Time to Time, of up to 5.4 Mln Shares of Common Stock by Selling Stockholder
H.C. Wainwright Maintains Vigil Neuroscience(VIGL.US) With Buy Rating, Cuts Target Price to $14